50POST — Every State. Every Story. My 50POST ↗
LAWS & TAXES / BRIEFING

Agency notice: FDA proposes withdrawing approval for Flolipid suspension

Federal · applicability depends on the document

50POST news graphic: Agency notice: FDA proposes withdrawing approval for Flolipid suspension
50POST news graphic · story-specific information

The FDA is proposing to withdraw approval of NDA 206679 for Flolipid suspension in 20 milligrams/5 milliliters and 40 milligrams/5 milliliters.

The agency says the proposal follows Salerno Pharmaceuticals’ repeated failure to file required annual reports for the application.

Salerno Pharmaceuticals may request a hearing on the proposal.

Based on the linked record from Federal Register ↗. Our reporting and verification standards.

A federal document is not a determination of how a law applies to you. A published rule may have a separate effective date. Consult the official record for its terms.
Source, dates and supporting record
Source published
Nov 18, 2026
Last checked
Nov 19, 2026, 2:45 PM EST
Record status
Agency notice
Comment deadline
Jan 19, 2027

Read the original record ↗

Supporting excerpts

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno
The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679.
Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal.

Original source text

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal. The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679.

Source wording and its time zone may differ. Date-only dates are preserved. Timestamps here use Eastern Time. Evidence version: c607434c77ee11932eb460501ae78a56c1a07e3bf01c1bbd19724b11da85959e

Source guidance

Consult the linked document and official PDF. Publication does not by itself establish that a rule is currently in force.

Original guidance from the issuing source. For current warnings and instructions, consult that source directly. This site is not an emergency notification service.

Something doesn’t look right?

Tell the editor what needs checking. Please avoid personal or sensitive details.

Sign in if needed to submit a report